CVS Health Raises 2026 Guidance After Strong Q1 Beat and Better Cost Controls
CVS had strong Q1: revenue $100.4B, earnings beat expectations, raised outlook, cash flow up. Stock rose.
CVS had strong Q1: revenue $100.4B, earnings beat expectations, raised outlook, cash flow up. Stock rose.
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.
Tempus AI revenue rose 36% to $348M, but losses widened. Stock fell ~7% after weaker profit and cautious outlook.
Summit stock fell after its cancer drug update was just “keep going,” not the big win investors hoped for.
Moderna beat Q1 revenue on strong overseas COVID vaccine sales, revenue $389M, smaller US demand, reported a per-share loss.
Eli Lilly raised profit outlook thanks to strong Zepbound & Mounjaro sales; revenue and earnings beat expectations, stock rose.